Security
Incannex Healthcare Inc. Common Stock · IXHL
IXHLNASDAQCommon stockCurrentCIK 1873875Updated Oct 29, 2026
Name history
Incannex Healthcare Ltd · through Nov 29, 2023
IXHL price & chart
Loading TradingView…
NASDAQ:IXHL on TradingView ↗About the company
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 80,283,000Source | 16,197,000Source | 17,250,000Source | 75,006,000Source | 11,106,000Source | 22,359,000Source | 78,720,000Source | 16,048,000Source | 72,979,000Source | 20,447,000Source | 17,047,000Source | 88,590,700Source |
| Property, Plant and Equipment, NetUSD | 47,000Source | 277,000Source | 523,000Source | 108,000Source | 273,000Source | 559,000Source | 168,000Source | 428,000Source | 4,000Source | 227,000Source | 472,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 74,450,000Source | 6,711,000Source | 9,305,000Source | 68,900,000Source | 2,098,000Source | 14,554,000Source | 73,280,000Source | 3,627,000Source | 67,711,000Source | 15,039,000Source | 5,858,000Source | — |
| Assets, CurrentUSD | 80,095,000Source | 15,629,000Source | 16,319,000Source | 74,678,000Source | 10,504,000Source | 21,332,000Source | 78,295,000Source | 15,209,000Source | 72,827,000Source | 19,962,000Source | 16,202,000Source | — |
| Prepaid Expense and Other Assets, CurrentUSD | 405,000Source | 416,000Source | 7,014,000Source | 431,000Source | 417,000Source | 6,778,000Source | 486,000Source | 489,000Source | 537,000Source | 791,000Source | 507,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 114,000Source | 291,000Source | 408,000Source | 163,000Source | 329,000Source | 468,000Source | 212,000Source | 411,000Source | 97,000Source | 258,000Source | 373,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,049,000Source | 8,794,000Source | 3,112,000Source | 1,600,000Source | 10,141,000Source | 3,487,000Source | 1,712,000Source | 9,453,000Source | 5,606,000Source | 7,058,000Source | 5,830,000Source | 4,461,833Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 41,000Source | 2,000Source | 2,000Source | 36,000Source | 2,000Source | 2,000Source | 35,000Source | 2,000Source | 38,000Source | 20,000Source | 2,000Source | — |
| Additional Paid in CapitalUSD | 253,216,000Source | 136,849,000Source | 122,004,000Source | 247,042,000Source | 126,354,000Source | 119,887,000Source | 243,837,000Source | 125,677,000Source | 247,769,000Source | 174,049,000Source | 125,218,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -174,367,000Source | -125,953,000Source | -104,210,000Source | -170,484,000Source | -121,984,000Source | -98,179,000Source | -163,963,000Source | -116,091,000Source | -176,858,000Source | -157,556,000Source | -110,671,000Source | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,656,000Source | -3,495,000Source | -3,658,000Source | -3,188,000Source | -3,407,000Source | -2,838,000Source | -2,901,000Source | -2,993,000Source | -3,576,000Source | -3,124,000Source | -3,332,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 75,234,000Source | 7,403,000Source | 14,138,000Source | 73,406,000Source | 964,000Source | 18,872,000Source | 77,008,000Source | 6,595,000Source | 67,373,000Source | 13,389,000Source | 11,217,000Source | — |
| Additional Paid in Capital, Common StockUSD | — | — | — | — | — | — | — | — | 247,769,000Source | 174,049,000Source | — | — |
| Liabilities and EquityUSD | 80,283,000Source | 16,197,000Source | 17,250,000Source | 75,006,000Source | 11,106,000Source | 22,359,000Source | 78,720,000Source | 16,048,000Source | 72,979,000Source | 20,447,000Source | 17,047,000Source | — |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,927,000Source | 7,368,000Source | 2,864,000Source | 1,547,000Source | 5,840,000Source | 3,186,000Source | 1,648,000Source | 9,232,000Source | 1,492,000Source | 6,984,000Source | 5,620,000Source | — |
| Operating Lease, Liability, CurrentUSD | 72,000Source | 186,000Source | 161,000Source | 110,000Source | 177,000Source | 169,000Source | 146,000Source | 190,000Source | 62,000Source | 184,000Source | 163,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 42,000Source | 104,000Source | 248,000Source | 53,000Source | 152,000Source | 301,000Source | 64,000Source | 221,000Source | 34,000Source | 74,000Source | 210,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 202,000Source | 4,358,000Source | 1,133,000Source | 133,000Source | 3,066,000Source | 734,000Source | 154,000Source | 7,100,000Source | 242,000Source | 661,000Source | 4,512,000Source | — |
| DeferredTaxAssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 3,988,448Source |
| IntangibleAssetsOtherThanGoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 52,717,427Source |
| IssuedCapitalUSD | — | — | — | — | — | — | — | — | — | — | — | 150,842,248Source |
| TradeAndOtherCurrentPayablesUSD | — | — | — | — | — | — | — | — | — | — | — | 3,675,090Source |
| TradeAndOtherCurrentReceivablesUSD | — | — | — | — | — | — | — | — | — | — | — | 287,478Source |
| UnusedTaxLossesForWhichNoDeferredTaxAssetRecognisedUSD | — | — | — | — | — | — | — | — | — | — | — | 29,636,125Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossUSD | — | — | — | — | — | — | — | — | — | — | — | -19,979,558Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,626,000Source | 459,000Source | 7,559,000Source | 2,609,000Source | 8,928,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -9,163,000Source | -2,245,000Source | -12,867,000Source | -12,513,000Source | -15,845,000Source | — |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -42,000Source | — | -94,000Source | -8,000Source | -277,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,000Source | — | 10,000Source | 8,000Source | 277,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 9,397,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 67,177,000Source | -52,000Source | 65,903,000Source | 21,396,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 74,450,000Source | 6,711,000Source | 69,193,000Source | 2,098,000Source | 73,280,000Source | 3,627,000Source | 67,711,000Source | 15,039,000Source | 5,858,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 269,000Source | 14,000Source | -270,000Source | 306,000Source | -140,000Source | — |
| Additional Financial Items | ||||||||||||
| AdjustmentsForSharebasedPaymentsUSD | — | — | — | — | — | — | — | — | — | — | — | 3,191,640Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | -1,468,000Source | -416,000Source | -2,279,000Source | -435,000Source | -2,626,000Source | -459,000Source | 7,559,000Source | 2,609,000Source | 8,928,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 66,000,000Source | 66,184,000Source | 240,000Source | 143,000,000,000Source | 103,000,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 25,000Source | 41,000Source | -24,000Source | -326,000Source | -13,000Source | -5,000Source | -13,000Source | -289,000Source | -28,000Source | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -13,000Source | -5,000Source | -15,000Source | -294,000Source | -28,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | -994,000Source | — | — | — | — | 0Source | -1,472,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 3,727,000Source | 2,268,000Source | 4,715,000Source | 3,602,000Source | 5,674,000Source | 3,432,000Source | 17,817,000Source | 13,128,000Source | 17,174,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -44,000Source | — | 11,000Source | — | 6,000Source | — | -37,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | 30,000Source | — |
| InterestExpenseNonoperatingUSD | — | — | — | 132,000Source | -5,000Source | -28,000Source | -5,000Source | -28,000Source | 0Source | 303,000Source | — | — |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 329,157Source |
| Investment Income, InterestUSD | — | — | — | 4,000Source | — | 28,000Source | — | 28,000Source | 21,000Source | 62,000Source | 206,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,883,000Source | -3,968,000Source | -6,521,000Source | -5,894,000Source | -6,407,000Source | -5,420,000Source | -19,302,000Source | -46,885,000Source | -18,459,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 165,000Source | 1,035,000Source | 474,000Source | -890,000Source | 387,000Source | 834,000Source | 3,725,000Source | -23,096,000Source | 11,612,000Source | — |
| Operating ExpensesUSD | — | — | 4,048,000Source | 5,003,000Source | 6,995,000Source | 5,016,000Source | 6,794,000Source | 6,328,000Source | 23,027,000Source | 23,875,000Source | 30,053,000Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 54,717Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 69,465,000Source | — | 78,667,000Source | 48,343,000Source | — | — |
| ProceedsFromIssuingSharesUSD | — | — | — | — | — | — | — | — | — | — | — | 12,330,284Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | 12,000Source | — | 74,000Source | 0Source | 86,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | — | —Source | — | — | — | — | — | — |
| Operating Lease, Lease Income | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | 12,000Source | — | 74,000Source | — | — | 12,000Source | — |
| Operating Income (Loss)USD | — | — | -4,048,000Source | -5,003,000Source | -6,995,000Source | -5,004,000Source | -6,794,000Source | -6,254,000Source | -23,027,000Source | -23,789,000Source | -30,041,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,883,000Source | -3,968,000Source | -6,521,000Source | -5,894,000Source | -6,407,000Source | -5,420,000Source | -19,302,000Source | -46,885,000Source | -18,429,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | 30,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,883,000Source | -3,968,000Source | -6,521,000Source | -5,894,000Source | -6,407,000Source | -5,420,000Source | -19,302,000Source | -46,885,000Source | -18,459,000Source | — |
| Earnings Per Share, BasicUSD per share | — | — | -0.35Source | -6.19Source | — | — | — | — | -1.66Source | -1.35Source | -1.15Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.35Source | -6.19Source | — | — | — | — | -1.66Source | -1.35Source | -1.15Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 12,348,460Source | 654,418Source | — | — | — | — | 11,658,374Source | 34,454,269Source | 16,164,338Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 12,348,460Source | 654,418Source | — | — | — | — | 11,658,374Source | 34,454,269Source | 16,164,338Source | — |
| Interest Expense (non-operating)USD | — | — | — | 132,000Source | -5,000Source | -28,000Source | -5,000Source | -28,000Source | 0Source | 303,000Source | — | — |
| Additional Financial Items | ||||||||||||
| AdministrativeExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 568,954Source |
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | — | — | — | 0.25Source |
| AverageEffectiveTaxRatenumber | — | — | — | — | — | — | — | — | — | — | — | 0.3Source |
| BasicEarningsLossPerShareUSD per share | — | — | — | — | — | — | — | — | — | — | — | -1.3Source |
| Business Combination, Acquisition Related CostsUSD | — | — | — | — | — | — | — | — | — | — | 35,300,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 66,000Source | 64,000Source | 240,000Source | 246,000Source | 103,000Source | — |
| DepreciationRightofuseAssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 97,726Source |
| DilutedEarningsLossPerShareUSD per share | — | — | — | — | — | — | — | — | — | — | — | -1.3Source |
| EmployeeBenefitsExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 3,490,754Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 25,000Source | 41,000Source | -24,000Source | -326,000Source | -13,000Source | -5,000Source | -13,000Source | -289,000Source | -28,000Source | — |
| General and Administrative ExpenseUSD | — | — | 3,727,000Source | 2,268,000Source | 4,715,000Source | 3,602,000Source | 5,674,000Source | 3,432,000Source | 17,817,000Source | 13,128,000Source | 17,174,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -44,000Source | — | 11,000Source | — | 6,000Source | — | -37,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 4,000Source | — | 28,000Source | — | 28,000Source | 21,000Source | 62,000Source | 206,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 165,000Source | 1,035,000Source | 474,000Source | -890,000Source | 387,000Source | 834,000Source | 3,725,000Source | -23,096,000Source | 11,612,000Source | — |
| Operating ExpensesUSD | — | — | 4,048,000Source | 5,003,000Source | 6,995,000Source | 5,016,000Source | 6,794,000Source | 6,328,000Source | 23,027,000Source | 23,875,000Source | 30,053,000Source | — |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 1,144,000Source | 932,000Source | 823,000Source | — |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 10,800,000Source | 1,376,645Source |
| OtherOperatingIncomeExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,376,645Source |
| ProfitLossBeforeTaxUSD | — | — | — | — | — | — | — | — | — | — | — | -19,979,558Source |
| Research and Development ExpenseUSD | — | — | 321,000Source | 2,735,000Source | 2,280,000Source | 1,414,000Source | 1,120,000Source | 2,896,000Source | 5,210,000Source | 10,747,000Source | 12,879,000Source | 9,364,796Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | 12,000Source | — | 74,000Source | 0Source | 86,000Source | — | — |
| RevenueFromInterestUSD | — | — | — | — | — | — | — | — | — | — | — | 362,766Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | — | —Source | — | — | — | — | — | — |
| Interest Income (Expense), Nonoperating, Net | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Operating Lease, Lease Income | — | — | — | — | — | — | — | —Source | — | — | — | — |
Filing attachments
ea030478201ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 ea030478201ex99-1.htm PRESS RELEASE DATED AS OF SEPTEMBER 9, 2026 Exhibit 99.1 Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040 Approximately $70 million in cash and no debt, including more than A$11.2…
Read attachment ↗ea030314001ex99-1.htm · 8-K · 2026-08-25
EX-99.1 2 ea030314001ex99-1.htm PRESS RELEASE DATED AS OF AUGUST 25, 2026 Exhibit 99.1 Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation NEW YORK and MELBOURNE, Australia, August 25, 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinica…
Read attachment ↗ea030133301ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ea030133301ex99-1.htm PRESS RELEASE DATED AS OF AUGUST 11, 2026 Exhibit 99.1 Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 Completion of more than A$11.2 million in non-dilutive capital received under the Australian Government’s R&D Tax Incentive Program further strengthens Company’s balance sheet and financial flexibility NEW YORK and MELBOURNE, Australia, Tuesday, 11 August, 202…
Read attachment ↗ea029867401ex99-1.htm · 8-K · 2026-07-23
EX-99.1 2 ea029867401ex99-1.htm PRESS RELEASE DATED AS OF JULY 23, 2026 Exhibit 99.1 Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea First clinical sites approved and actively screening potential participants Represents another major milestone in the advancement of IHL-42X towards Phase III development IHL-42X has received FDA Fast Track designation, highlighting its potential to address the significant unmet medical …
Read attachment ↗ea029576901ex99-1.htm · 8-K · 2026-06-25
EX-99.1 2 ea029576901ex99-1.htm PRESS RELEASE DATED AS OF JUNE 25, 2026 Exhibit 99.1 Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnoea MELBOURNE, Australia and NEW YORK, 25 June 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the United States Patent and Trademark Office (USPTO) has granted a key pate…
Read attachment ↗ea029391701ex99-1.htm · 8-K · 2026-06-10
EX-99.1 2 ea029391701ex99-1.htm PRESS RELEASE DATED AS OF JUNE 10, 2026 Exhibit 99.1 Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026. NEW YORK and ME…
Read attachment ↗